In a randomized trial, a 4-day quinine-clindamycin regimen was compared with the standard 7-day quinine regimen for 100 Gabonese children (50 children in each group) with severe Plasmodium falciparum malaria. In each group, only one patient died. Parasite clearance and fever clearance times were significantly shorter in the quinine-clindamycin group (P ‫؍‬ 0.03 and P ‫؍‬ 0.01, respectively) than in the quinine group, and significantly more recurring fever episodes occurred in the quinine group than in the quinine-clindamycin group shortly after initial fever clearance and parasite clearance (P < 0.001).
Each year more than 10 million African children suffer from severe Plasmodium falciparum malaria, and more than 1 million die. The vast majority of these children receive parenteral quinine therapy. However, the usually recommended 7-day regimen causes compliance problems if the children leave the hospital before treatment is finished (11) . Short-term quinine regimens were not sufficient to cure Gabonese schoolchildren of even uncomplicated P. falciparum malaria (4) . Previous studies also revealed a considerable rate of concomitant bacteremia and/or septicemia or localized bacterial infections of patients with severe malaria (8, 9) . In southeast Asia, tetracyclines are commonly combined with quinine for treating P. falciparum malaria (11) . However, because of the side effects of these antibiotics, this combination cannot be used for children and pregnant women, the two groups most vulnerable to severe malaria. Clindamycin is a lincosamide antibiotic with antiplasmodial properties which can be given to children (3) . The use of clindamycin in combination with quinine for treating human volunteers with chloroquine-resistant malaria was first described two decades ago (7) . In comparative trials, clindamycin combined with quinine improved the cure rate of uncomplicated P. falciparum malaria for patients in Africa and South America (4) (5) (6) . On the basis of this rationale, we have compared the 7-day quinine regimen with a 4-day quinineclindamycin regimen for treating Gabonese children with severe malaria.
The study took place at the Albert-Schweitzer-Hospital in Lambaréné, Gabon. All children with severe P. falciparum malaria treated at the hospital were enrolled. The children had to fulfill at least one of the following criteria: hyperparasitemia (Ն250,000 parasites per l), severe anemia (hemoglobin score of Ͻ50 g/liter or hematocrit score of Ͻ15%), hypoglycemia (glucose, Ͻ2.2 mmol/liter), or cerebral malaria (unrousable coma not attributable to another cause) (10) . Children with sickle cell anemia or younger than 6 months were not included. Parents or guardians gave informed consent. The study was approved by the International Foundation of the Albert-Schweitzer-Hospital. The children were randomly allocated to two treatment groups. One group received the World Health Organization standard treatment with intravenous quinine, initially a 16-mg base per kg of body weight over 4 h, then 8 mg/kg every 8 h administered in continuous 5% glucose infusions for 11 doses, and thereafter 12 mg/kg given orally every 12 h to complete the 7-day regimen. The other group received quinine as described above for 12 doses plus intravenous clindamycin, initially with a 5-mg base per kg given as a short infusion followed 4 h later by short 5-mg/kg infusions every 8 h for 11 doses. The patients were hospitalized for 7 days. During the initial 4 days, vital signs were recorded and clinical examinations were performed every 4 to 8 h. Rectal temperature was measured every 8 h for 7 days. The parasitemia level was determined every 8 h until three consecutive blood smears were negative. Hemocultures of samples from the last 59 patients were performed by using the Oxoid Signal System (Unipath, Basingstoke, England), and the isolated bacterial strains were identified and further characterized as previously described (8) . The hematological and biochemical parameters of the patients were determined at least every 24 h for 7 days. Supportive treatment (e.g., blood transfusion or glucose administration) was given as required. Thick blood smears and clinical checks were performed on day 14, 21, and 28 to determine the parasite recrudescence rate. The two treatment groups were statistically compared by the Mann-Whitney U test and the chi-square test.
One hundred children with severe malaria were enrolled in the study. Their prominent clinical feature was severe anemia with hyperparasitemia. The two groups were well comparable with regard to baseline clinical and laboratory findings (Table  1 ). There was no difference between the final cure rates of the groups. Only four patients in the quinine group and two in the quinine-clindamycin group showed parasite recrudescences by day 28 of the follow-up. In addition, one patient in the quinine group died 7 h after admission and one in the quinine-clindamycin group died 20 h after admission. However, parasite clearance and fever clearance times were significantly shorter for the quinine-clindamycin group (P ϭ 0.03 and P ϭ 0.01, respectively) than for the quinine group. Moreover, significantly more patients in the quinine group than in the quinineclindamycin group showed a recurrent fever episode shortly after initial fever clearance and parasite clearance (P Ͻ 0.001) ( Table 1 ). These recurrent fever episodes appeared within 8 h to 3 days after parasite clearance. No parasite recrudescences were found during these fever episodes which waned in most cases after 1 or 2 days without treatment. For 59 consecutive patients from the present study, hemocultures were done on admission and seven of the cultures yielded positive results. The identified bacterial strains included three Staphylococcus aureus, one Klebsiella pneumoniae, one Serratia marcescens, one Pseudomonas cepacia, and one Moraxella liquefaciens strain. The patient with K. pneumoniae died 20 h after admission. From the other patient who died, no hemoculture was done. Hemocultures were done during the same period for a control group of 45 children with uncomplicated P. falciparum malaria (age, 1 to 6 years; parasitemia count, 2,000 to 120,000 parasites per l), and none was positive.
Our study indicates that the addition of clindamycin to the standard quinine treatment substantially improves and shortens the chemotherapy of African children with severe malaria. As clindamycin is a slowly acting antimalarial agent, it should be used as a single agent only for treating semi-immune malaria patients (3) . However, combined with the fast-acting quinine, it enhanced parasite clearance, as shown in the present study and in previous trials involving patients with uncomplicated P. falciparum malaria (4, 5) . From these studies, it be-came obvious that not only the antiparasitic activity of clindamycin but also other properties, including its possible antibacterial effect, may be of value in the treatment of severe malaria. As reported earlier (8) and demonstrated again in the present trial, bacteremia seems to be a common event for African children with severe malaria. This infection may worsen the clinical condition either by prolonging fever, by causing additional fever episodes, or even by leading to septic shock. We assume that damage of the endothelial lining in various organs (e.g., intestine and lung) during severe malaria (1, 2) allows bacteria to enter the bloodstream. The concomitant immunodepression may facilitate the development of bacteremia. The reduced fever clearance time and the reduced number of recurring fever episodes in the quinine-clindamycin group could partly be a beneficial effect of clindamycin on concurrent bacterial infections. However, this does not imply that clindamycin should be considered a highly efficient antibiotic to prevent bacterial infections complicating severe malaria. In conclusion, the present study demonstrated that quinine-clindamycin favorably compared with the standard quinine treatment. The slightly increased costs of the quinineclindamycin regimen may be equalized by a possibly reduced time of hospitalization. a Data indicate means (standard deviations) or numbers of patients, except parasitemia, for which medians (ranges) are given. b P ϭ 0.03, P ϭ 0.01, and P Ͻ 0.001 for differences between groups in parasite clearance, fever clearance, and the number of patients with recurrent fever episodes, respectively.
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